Joshua M DeMott

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2021
Publications (10 Years): 6

Top Topics

Staphylococcus Aureus

Prognostic Factors

Ejection Fraction

Replacement Therapy

Top Venues

Journal of pharmacy practice

The Annals of pharmacotherapy

Pharmacotherapy

Rush University Medical Center

Rush University (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Rush University Medical Center Jan 01 2012

United States

Clinical Pharmacy Specialist - Critical Care :: Pharmacy

Education History

Rush University Sep 01 2015 - Jun 05 2017

United States

MSC

Ferris State University Aug 01 2005 - May 02 2009

United States

PHD

Publications

Mariana G Mallidi, Giles W Slocum, Gary Daniel Peksa, Joshua M DeMott
Impact of Prior-to-Admission Methicillin-Resistant Staphylococcus aureus Nares Screening in Critically Ill Adults With Pneumonia. The Annals of pharmacotherapy (2021)
Michael A DiCesare, Megan A Rech, Joshua M DeMott
Predictors of a response to dexmedetomidine in intubated, critically ill adult patients. Pharmacotherapy 41 (2) (2021)
Payal K Gurnani, Gary D Peksa, Nicholas G Panos, Joshua M DeMott
Under the Microscope: A Look Into the Role of Critical Care Pharmacists During the COVID-19 Pandemic. Journal of pharmacy practice (2021)
Alfredo Traversa, Drayton A Hammond, Gary D Peksa, Joshua M DeMott
Short Versus Extended Duration Vancomycin and Piperacillin/Tazobactam and the Incidence of Acute Kidney Injury in Noncritically Ill Patients. Journal of pharmacy practice 34 (6) (2020)
Lauren Fay, Georgeanna Rechner-Neven, Drayton A Hammond, Joshua M DeMott, Mary Jane Sullivan
Evaluating the Risk of Developing Thrombocytopenia Within Five Days of Continuous Renal Replacement Therapy Initiation in Septic Patients. Journal of pharmacy practice (2020)
Attiya A Khan, Payal K Gurnani, Gary Daniel Peksa, William L Whittier, Joshua M DeMott
Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy. The Annals of pharmacotherapy 55 (3) (2020)